Solvay Pharmaceuticals S.A. increases to eur 6.50 per share its initial tender offer to acquire Innogenetics

Solvay Pharmaceuticals S.A., a subsidiary of Solvay, the chemical and pharmaceutical group, today announced that it will increase its initial conditional tender offer to acquire Innogenetics N.V., a Belgian-based biotechnological company, in a cash transaction valued at EUR 6.50 per share.